Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients
Oncogenesis · 11.07.2024 · 13 (1)
DOI: 10.1038/s41389-024-00525-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncogenesis, online erschienen am 11.07.2024. Verfasst von Anne M van Harten und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, De Boel…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding (Dutch Cancer Society).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2′, 2′-difluoro 2′deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg−/− mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing.
Autor:innen und Institutionen
- Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
- Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. rh.brakenhoff@amsterd…
- Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands. rh.brakenhoff@amsterdamumc.nl.
Förderung
- KWF Kankerbestrijding (Dutch Cancer Society)
Zitieren
APA
van Harten, A. M., Shah, R., de Boer, D. V., Buijze, M., Kreft, M., Song, J. Y., Zürcher, L. M., Jacobs, H., & Brakenhoff, R. H. (2024). Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients. Oncogenesis, 13(1). https://doi.org/10.1038/s41389-024-00525-2
Vancouver
van Harten AM, Shah R, de Boer DV, Buijze M, Kreft M, Song JY, et al. Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients. Oncogenesis. 2024;13(1). doi:10.1038/s41389-024-00525-2
BibTeX
@article{vanHarten2024,
author = {van Harten, Anne M and Shah, Ronak and de Boer, D Vicky and Buijze, Marijke and Kreft, Maaike and Song, Ji-Ying and Zürcher, Lisa M and Jacobs, Heinz and Brakenhoff, Ruud H},
title = {Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients},
journal = {Oncogenesis},
year = {2024},
volume = {13},
number = {1},
doi = {10.1038/s41389-024-00525-2}
}
EUVIMED